Description:
HIFResponsiveLuciferaseReporterHelaStableCellLineisderivedfromhumancervicalcancer,andstablyexpressfireflyluciferasereportergeneunderthecontrolofHIFresponseelement. ThiscelllineisanidealcellularmodelformonitoringtheactivationofHypoxiaResponseSignalingReceptorSignalingPathwaytriggeredbystimulitreatment,enforcedgeneexpressionandgeneknockdown.Principle:
Hypoxia-InducIBLeFactor(HIF)-1isadimericproteincomplexthatplaysacentralroleintheresponsetolowoxygenconcentrations,orhypoxia,and isacrucialphysiologicalregulatorofhomeostasis,vascularization,andanaerobicmetabolism.HIFisatranscriptionfactorregulatinggeneexpressionbybindingtotheirDNArecognitionsiteonthetargetgenes.FurThermore,HIF-1hasbeenwidelystudiedbecauseofitsperceivedtherapeuticpotential. HIF-1allowssurvivalandproliferationofcancerouscellsduetoitsangiogenicproperties,andtheinhibitionpotentiallycouldpreventthespreadofcancer.WithagrowingunderstandingoftheHIF-1pathway,ithasbecomeanattractivegoaltoanalyzetheinhibitionandstimulationofHIFtranscriptionalactivityviasmallmolecules.
Signosishasdeveloped HIFLuciferaseReporterStableCellLinebytransfectionofHIFluciferasereportervectoralongwithhygromycinexpressionvectorfollowedbyhygromycinselection.ThehygromycinresistantclonesweresubsequentlyscreenedforCoCl2ordeferroxamine-inducedluciferaseactivity.
PrinciplebehindTFluciferasereporter. TFluciferasereporterstablecelllineutilizesartificialpromoterconstructstodriveluciferaseexpression. Thepromoterregioncanconsistsofmultiplerepeatsofacis-elementTFbindingsite,aDNAfragmentfromthepromoterregionofaknownTFdownstreamgene,oraDNAfragmentcontainingputative/knownTFbindingsites. ThereareseveralwaysthataTFcanbeactivated,suchasthroughextracellularstimuliorthroughintracellularsignalingpathways. Onceactivated,theTFtranslocatestothenucleusandofteninteractswithrelevantco-factorstodrivegeneexpression. Onceluciferaseisexpressed,itcangeneratelightinanenzymaticassayandtheamountoflightmeasuredispositivelycorrelatedwiththelevelofTFactivation. |
Data:
AnalysisofSL-0023HIFreporteractivityinresponsetoDFOtreatment. TheHelacellswereseededona96-wellplateforovernightwithDMEMincluding10%FBS.Thecellsthenweretreatedwithorwithoutvaryingdoseofdeferoxamine(DFO)inDMEMand10%FBSfor18hours. Hela-HIFLuciferaseReporterCellLineexhibitsdose-dependentincreaseinluciferaseactivitywhencomparedtountreatedcells.
